Category

News

PamGene announces 7 poster presentations from its collaborators at the AACR meeting in San Diego, highlighting innovative applications of its kinase activity profiling platform

‘s-Hertogenbosch, the Netherlands, March 21, 2024 – PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, announced today the presentations of seven posters from...
Read More

PamGene awarded €7.5 million EIC Accelerator funding to develop and market its IOpener® blood test for the prediction of immunotherapy response in metastatic cancer

‘s-Hertogenbosch, The Netherlands, June 27, 2023 PamGene International B.V., an in-vitro diagnostics and biomarker services company developing a blood-based cancer immunotherapy guidance test called IOpener®, is one of the 51...
Read More

PamGene at the AACR 2023!

PamGene, together with collaborators, presented insightful Applications of our kinase activity profiling technology through Posters and at our Booth # 75
Read More

PamGene, Alithea Genomics and Lausanne University Hospital (CHUV) secure Eurostars funding to develop a first-of-a-kind pan-cancer blood test for the prediction of immunotherapy efficacy and toxicity

‘s-Hertogenbosch, the Netherlands; Lausanne, Switzerland – January 17, 2023 MAINLINE, a Dutch-Swiss consortium between PamGene International B.V., Alithea Genomics SA and Lausanne University Hospital (CHUV), has been awarded a Eurostars...
Read More

PamGene announces results of its IOpener®-NSCLC test to predict response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer at the 2022 ESMO Immuno-Oncology meeting in Geneva, Switzerland

‘s-Hertogenbosch, the Netherlands, December 1, 2022 PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, will present the results of its IOpener®-NSCLC test on...
Read More

PamGene attains IVDD registration for its IOpener®-NSCLC immunotherapy guidance test in Europe

‘s-Hertogenbosch, the Netherlands, July 21, 2022 PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, today announced its IOpener®-NSCLC test has been registered as...
Read More

PamGene attains IVDD registration for its IOpener®-melanoma immunotherapy guidance test in Europe

‘s-Hertogenbosch, the Netherlands, July 5th, 2022 PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, today announced its IOpener®-melanoma test has been registered as...
Read More

PamGene receives ISO 13485:2016 from DEKRA Certification B.V. for its IOpener® immunotherapy response prediction test devices

‘s-Hertogenbosch, the Netherlands, March 29th, 2022 PamGene International B.V., an in-vitro diagnostics company focused on the development and commercialization of blood-based immunotherapy response prediction tests, today announced it has received...
Read More

Meet our specialists – Savithri Rangarajan

“Making the most out of kinase activity data to take scientific research to the next level is what gets me excited” PamGene’s kinase activity profiling data provides scientists with new...
Read More

Review paper: The past and current trends of kinase research and use of high-throughput active kinome technologies

Recently the University of Toledo published a review paper in ‘The current opinion in pharmacology’. In this review, the authors examine the past and current trends of kinase research and...
Read More
1 2 3 4 5